ArticleJournal of visualized experiments : JoVE2025
Development of Mouse Models for Ménétrier's Disease.
Article in Journal of visualized experiments : JoVE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in spasmolytic polypeptide expressing metaplasia research.World journal of gastrointestinal oncology · 2026Review
- Transcriptomic profiling reveals the role of Hedgehog signaling as a biomarker and in the pathogenesis of Ménétrier's disease.The Journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ménétrier's disease (MD) is a rare acquired premalignant gastric disorder characterized by giant rugal folds, decreased acid secretion, and protein loss. MD patients show increased expression of an EGF receptor (EGFR) ligand, transforming growth factor-α (TGFα) in the stomach. The EGFR-neutralizing antibody, cetuximab, results in rapid clinical improvement and histological remission. Beyond these findings, the etiology and underlying molecular mechanisms are not well understood. The Metallothionein (MT)-TGFα transgenic mouse line is the first MD mouse model that recapitulates histopathological features of MD, including foveolar hyperplasia and loss of parietal cells. In this mouse model, TGFα is driven by the heavy metal-inducible MT enhancer/promoter. Prior studies have used zinc sulfate (ZnSO4) in drinking water or intraperitoneal injections of cadmium sulfate (CdSO4) to induce TGFα. However, we found that MT-TGFα mice develop phenotypes without heavy metal treatment, indicating leakiness of the promoter. We also found that overexpression of TGFα suppresses Mist1 expression, a transcription factor important for chief cell differentiation, thus hindering genetic manipulation in chief cells using the Mist1-CreERT2 mouse line. To overcome this, we developed an inducible mouse model (Doxi-TGFα) in which TGFα is induced by doxycycline treatment (CMV-rtTA; TetO-TGFα). Although the Doxi-TGFα mouse model develops milder phenotypes than the MT-TGFα model, it recapitulated features of MD, including foveolar hyperplasia and loss of parietal cells. Using the Doxi-TGFα mouse model, we found that spasmolytic polypeptide-expressing metaplasia (SPEM) is induced in MD, and SPEM is derived from chief cells by lineage tracing using the Mist1-CreERT2 mouse line. Both MT-TGFα and Doxi-TGFα mouse models offer in vivo models of MD and are useful for investigating the molecular mechanisms underlying MD pathogenesis and treatment options for the disease. The Doxi-TGFα mice will also be a useful model to study the effects of overexpression of TGFα in other tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.